Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Federal funding opportunity PAR-25-444 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes September 25, 2028

Program funding history

Synopsis

Who can apply

• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• City or township governments
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Private institutions of higher education
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• Independent school districts
• Native American tribal governments (Federally recognized)
• Native American tribal organizations (other than Federally recognized tribal governments)
• For profit organizations other than small businesses
• County governments
• Public and State controlled institutions of higher education
• State governments
• Special district governments
• Small businesses

Specific to this NOFO:For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system. Please contact the NCI Office of Cancer Centers (https://cancercenters.cancer.gov/) for assistance in determining the RCDC funding base. For Renewal (Type 2) applications, an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions. However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by NCI.Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources). Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters.cancer.gov/sites/default/files/PeerReviewFundingOrganizations.pdfNOTE: New (Type 1) applications cannot request evaluation for comprehensiveness status. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign…

How to apply

Similar grants

• Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
  PAR-26-149 · National Institutes of Health
• NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)
  PAR-27-088 · National Institutes of Health
• NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
  PAR-27-089 · National Institutes of Health
• Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)
  PAR-25-324 · National Institutes of Health · closes September 7, 2028
• Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
  PA-25-168 · National Institutes of Health · closes May 4, 2028
• Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
  PA-24-253 · National Institutes of Health · closes July 17, 2027